Healthcare Industry News: Allograft
News Release - May 4, 2006
ATS Medical Announces Addition to Board of DirectorsMINNEAPOLIS, May 4 (HSMN NewsFeed) -- Michael D. Dale, President and CEO of ATS Medical, Inc. (Nasdaq: ATSI ) today announced the appointment of Mr. Steven Anderson to the Company's Board of Directors.
Mr. Anderson comes to ATS with 25 years of medical device experience specializing in Clinical and Regulatory Affairs, Regulatory Compliance, Reimbursement, Quality and Operations. His technical and leadership expertise was developed with device manufacturers including Medtronic, St. Jude Medical, St. Croix Medical and Acorn Cardiovascular. Mr. Anderson also served as Director of the North American Medical Division of TUV Product Service; a European Union Medical Device Directive Notified Body where he focused on global compliance initiatives.
"The addition of Steve to our Board of Directors is designed to strengthen our Clinical and Regulatory Affairs capabilities, and help us refine a strategic approach that will efficiently move us through the government regulatory processes that our pending acquisition of 3F Therapeutics will require," said Mr. Dale. "Steve is a high energy person with a wealth of Regulatory Affairs experience. He has been an active advocate for the industry while serving on numerous policy committees and is currently involved in legislative reform initiatives with the FDA and CMS. He understands the intricacies and fundamental spirit of the regulatory process in ways that will help us design, develop and implement sound scientific processes and trials that will cogently demonstrate the clinical safety and efficacy of our forthcoming tissue technologies. We couldn't be happier that Steve has come on board and we look forward to his contributions to the continuing growth story at ATS Medical."
About ATS Medical
ATS Medical, Inc. manufactures and markets products and services focused on cardiac surgery. The company, global in scope, has been headquartered in Minneapolis since its founding in 1991. More than 100,000 ATS Open PivotŪ Heart Valves, which utilize a unique pivot design resulting in exceptional performance and low risk profile, have been implanted in patients worldwide. ATS Medical's focus on serving the cardiac surgery community is further strengthened by offerings that include ATS Simulus(TM) annuloplasty products for heart valve repair, Surgi-FrostŪ and Frost-Byte(TM) products for surgical cryoablation of cardiac arrhythmias, RTI-Cardiovascular for Allograft tissue services, QAS home monitoring services for anticoagulation therapy and the development of PARSUS blood filtration technology. The ATS Medical web site is http://www.atsmedical.com .
This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward looking statements as a result of a number of important factors, including the successful completion of the 3F Therapeutics acquisition, which is subject to the satisfaction of various conditions, including approval by the shareholders of ATS, as well as regulatory actions, competition, pricing pressures, supplier actions and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2005.
Source: ATS Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.